Cases & Deals

  • Home
  • Practices
  • Loxo Oncology acquires drug development program from administrators of RedX

Share

Loxo Oncology acquires drug development program from administrators of RedX

July 2017

Client(s) Loxo Oncology, Inc.

Jones Day advised biopharmaceutical company, Loxo Oncology, Inc., in connection with its $40 million acquisition of a drug development program aimed at treating leukemia from the administrators of RedX Pharma Plc.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.